UB Paderborn / Katalog / Suche / in CDI

High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy

Clinical cancer research, 2010-12, Vol.16 (23), p.5805-5813

2010

Link zum Volltext

Verfügbarkeit prüfen

Haemolysis during sample preparation alters microRNA content of plasma

PloS one, 2011-09, Vol.6 (9), p.e24145-e24145

2011

Link zum Volltext

Verfügbarkeit prüfen

The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2016-06, Vol.11 (6), p.789-800

2016

Link zum Volltext

Verfügbarkeit prüfen

Colorectal cancer survivorship: A systematic review and thematic synthesis of qualitative research

European journal of cancer care, 2021-07, Vol.30 (4), p.e13421-n/a

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study

The lancet oncology, 2017-10, Vol.18 (10), p.1386-1396

2017

Link zum Volltext

Verfügbarkeit prüfen

The Impact of Hemolysis on Cell-Free microRNA Biomarkers

Frontiers in genetics, 2013, Vol.4, p.94-94

2013

Link zum Volltext

Verfügbarkeit prüfen

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial

The lancet oncology, 2019-12, Vol.20 (12), p.1691-1701

2019

Link zum Volltext

Verfügbarkeit prüfen

Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma

Journal of thoracic oncology, 2017-09, Vol.12 (9), p.1421-1433

2017

Link zum Volltext

Verfügbarkeit prüfen

Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer

Epigenomics, 2016-08, Vol.8 (8), p.1079-1085

2016

Link zum Volltext

Verfügbarkeit prüfen

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2019-06, Vol.37 (16), p.1370-1379

2019

Link zum Volltext

Verfügbarkeit prüfen

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in

The lancet oncology, 2020-09, Vol.21 (9), p.1213-1223

2020

Link zum Volltext

Verfügbarkeit prüfen

Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma

Cancer, 2012-06, Vol.118 (11), p.2952-2961

2012

Link zum Volltext

Verfügbarkeit prüfen

Intravascular Ultrasound in the Creation of Transhepatic Portosystemic Shunts Reduces Needle Passes, Radiation Dose, and Procedure Time: A Retrospective Study of a Single-Institution Experience

Journal of vascular and interventional radiology, 2016-08, Vol.27 (8), p.1148

2016

Link zum Volltext

Verfügbarkeit prüfen

Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers

Journal of Clinical Pathology, 2013-10, Vol.66 (10), p.847-853

2013

Link zum Volltext

Verfügbarkeit prüfen

Immune checkpoint inhibitor-related hepatotoxicity: A review

World journal of gastroenterology : WJG, 2021-08, Vol.27 (32), p.5376-5391

2021

Link zum Volltext

Verfügbarkeit prüfen

Liquid biopsy in non‐small cell lung cancer: Is it ready for prime time yet?

Asia-Pacific journal of clinical oncology, 2023-04, Vol.19 (2), p.e3-e4

2023

Link zum Volltext

Verfügbarkeit prüfen

How long is too long? A scoping review of health system delays in lung cancer

European respiratory review, 2018-09, Vol.27 (149), p.180045

2018

Link zum Volltext

Verfügbarkeit prüfen

A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma

American journal of respiratory and critical care medicine, 2015-06, Vol.191 (12), p.1467-1469

2015

Link zum Volltext

Verfügbarkeit prüfen

COVID-19: the use of immunotherapy in metastatic lung cancer

Immunotherapy, 2020-06, Vol.12 (8), p.545-548

2020

Link zum Volltext

Verfügbarkeit prüfen

The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment

Lung cancer (Amsterdam, Netherlands), 2022-03, Vol.165, p.124-132

2022

Link zum Volltext

Verfügbarkeit prüfen

Balloon-occluded middle adrenal artery embolization and percutaneous microwave ablation of a metastatic adrenal tumor from renal cell carcinoma

Diagnostic and interventional radiology (Ankara, Turkey), 2022-09, Vol.28 (5), p.495-497

2022

Link zum Volltext

Verfügbarkeit prüfen

Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis

British journal of cancer, 2015-09, Vol.113 (6), p.963-969

2015

Link zum Volltext

Verfügbarkeit prüfen

Looking beyond the gunsight: A potential bailout technique for arterial and venous recanalization

Diagnostic and interventional radiology (Ankara, Turkey), 2022-05, Vol.28 (3), p.260-263

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of immunotherapy in KRAS -mutant non-small-cell lung cancer with comutations

Immunotherapy, 2021-08, Vol.13 (11), p.941-952

2021

Link zum Volltext

Verfügbarkeit prüfen

A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE

Nature communications, 2024-02, Vol.15 (1), p.1823-1823

2024

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy

Haemolysis during sample preparation alters microRNA content of plasma

The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non–Small Cell Lung Cancer

Colorectal cancer survivorship: A systematic review and thematic synthesis of qualitative research

Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study

The Impact of Hemolysis on Cell-Free microRNA Biomarkers

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial

Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma

Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in

Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma

Intravascular Ultrasound in the Creation of Transhepatic Portosystemic Shunts Reduces Needle Passes, Radiation Dose, and Procedure Time: A Retrospective Study of a Single-Institution Experience

Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers

Immune checkpoint inhibitor-related hepatotoxicity: A review

Liquid biopsy in non‐small cell lung cancer: Is it ready for prime time yet?

How long is too long? A scoping review of health system delays in lung cancer

A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma

COVID-19: the use of immunotherapy in metastatic lung cancer

The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment

Balloon-occluded middle adrenal artery embolization and percutaneous microwave ablation of a metastatic adrenal tumor from renal cell carcinoma

Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis

Looking beyond the gunsight: A potential bailout technique for arterial and venous recanalization

Efficacy of immunotherapy in KRAS -mutant non-small-cell lung cancer with comutations

A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE

Suchergebnisse filtern